Pharmacy Education and Resources for Providers

The information below is provided for CBH Providers.

Additional materials to share with members are available on the Pharmacy Education and Resources for Members page.

Shared Decision-Making in Child Psychiatry

Shared Decision-Making in Child Psychiatry: Insights From Philadelphia’s Family Peer Supports

Shared decision-making is a clinical approach in which the experience and expertise of the prescriber, patient, and family are regarded as equally important. Shared decision-making is characterized by collaboration, flexibility, and information-sharing that is initiated and sustained over time by the clinician.

Why Does This Matter? Clinician/parent disagreement has been linked with treatment dropout, whereas shared decision-making has been associated with greater treatment satisfaction. Discussion of patient and family member preferences is associated with achieving agreement in decision-making.

This information resource includes recommendations to clinicians from family peer support specialists in Philadelphia; the input is based on the experiences of peer support specialists when seeking care for family members within the CBH network of providers.

Long-Acting Injectable Antipsychotics (LAIs)

The CBH Pharmacy Team has created an LAI fact sheet for its Providers:

Despite being available for over 45 years, long-acting injectable antipsychotics (LAIs) remain an underutilized treatment option for people with serious and persistent mental illness. These injectable medications can help patients better manage their condition and improve long-term outcomes by preventing relapses and enhancing medication adherence.

LAIs are used primarily for individuals who struggle with adherence to antipsychotic medications. LAIs have been demonstrated through research to help:

  • Improve adherence
  • Reduce the occurrence and frequency of symptom relapse
  • Reduce rehospitalization
  • Improve treatment outcomes for this population

If you are a pharmacy within the Philadelphia area that offers LAI services and is not listed in the above resource, please contact the CBH Pharmacy Team at

Long-Acting Injectable Medications for Opioid Use Disorder

Effective treatment for opioid use disorder (OUD), including medication, is available to CBH members.

Among the Food and Drug Administration (FDA)-approved medications for OUD, there are three long-acting injectables (LAIs) available that do not need to be dosed daily:

  • Brixadi® (buprenorphine)
  • Sublocade® (buprenorphine)
  • Vivitrol® (naltrexone)

These LAIs expand the treatment options that are available to members with OUD. Benefits of LAI medications for OUD may include:

  • Helping maintain steady levels of medication
  • Improving adherence to treatment
  • Improving treatment satisfaction

For more information, please download our Long-Acting Injectable Medications for Opioid Use Disorder tip sheet.

Psychotropic Medications

Psychotropic medications affect a person’s behavior, mood, thoughts, or perception. There are different types of psychotropic medications, including:

  • Antidepressants
  • Antipsychotics
  • Anxiolytics
  • Mood Stabilizers
  • Stimulants

Clients may have to get lab work done if they are on certain medications, such as antipsychotics or mood stabilizers. They may measure the drug levels or other lab values to ensure the medication is helping and safe for the client.

HEDIS® Tip Sheets

Several of CBH’s Clinical Practice Guidelines (CPGs) utilize the Healthcare Effectiveness Data and Information Set (HEDIS®), a widely used set of performance measures in the managed care industry. CBH developed these HEDIS tip sheets in partnership with collaborating providers and the Southeastern Pennsylvania Medicaid MCOs that participate in the HealthChoices and Community HealthChoices programs as a resource for providers to summarize HEDIS metrics and parameters:

CBH Providers: Stay up to date by signing up for our News Blast